featured
Checkpoint Inhibitor–Associated Autoimmune Diabetes Characterised by C-Peptide Loss and Pancreatic Atrophy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Journal of Clinical Endocrinology and Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Checkpoint inhibitor associated autoimmune diabetes mellitus is characterised by C-peptide loss and pancreatic atrophy
J. Clin. Endocrinol. Metab. 2023 Nov 24;[EPub Ahead of Print], L Wu, MS Carlino, DA Brown, GV Long, R Clifton-Bligh, R Mellor, K Moore, SC Sasson, AM Menzies, V Tsang, JE GuntonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.